



*Handwritten initials: Hw*

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:  
Mail Stop Amendment, Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA 22313-1450 on

INFORMATION DISCLOSURE  
STATEMENT

Examining Group 1616  
Patent Application  
Docket No. UF-340XC1  
Serial No. 10/731,528  
Conf. No. 3723

August 18, 2004

*Handwritten signature of Margaret H. Efron*

Margaret H. Efron, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1616  
Applicant(s) : Laszlo Prokai, Katalin Prokai, James W. Simpkins, Neeraj Agarwal  
Serial No. : 10/731,528  
Filed : December 9, 2003  
For : Prodrugs for Use as Ophthalmic Agents

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



Margaret H. Efron  
Patent Attorney  
Registration No. 47,545  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: 2421 N.W. 41<sup>st</sup> Street, Suite A-1  
Gainesville, FL 32606-6669

MHE/la

Attachments: Form PTO/SB/08  
Copies of references cited (31 references)



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/731,528
				Filing Date	December 9, 2003
				First Named Inventor	Laszlo Prokai
				Art Unit	1616
				Examiner Name	Unknown
Sheet	1	of	3	Attorney Docket Number	UF-340XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-5,108,996	04-28-1992	Claussner <i>et al.</i>	All
	U2	US-5,395,831	05-07-1995	Gemmill, Jr. <i>et al.</i>	All
	U3	US-5,405,944	04-11-1995	Suzuki <i>et al.</i>	All
	U4	US-5,552,395	09-03-1996	Gemmill, Jr. <i>et al.</i>	All
	U5	US-5,554,601	09-10-1996	Simpkins <i>et al.</i>	All
	U6	US-5,859,001	01-12-1999	Simpkins <i>et al.</i>	All
	U7	US-6,096,733	08-01-2000	Lubkin	All
	U8	US-6,197,833 B1	03-06-2001	Simpkins <i>et al.</i>	All
	U9	US-6,258,856 B1	07-10-2001	Chamberlain <i>et al.</i>	All
	U10	US-6,319,914 B1	11-20-2001	Simpkins <i>et al.</i>	All
	U11	US-2002/0016340 A1	02-07-2002	Rosati	All
	U12	US-5,891,878	04-06-1999	Beasley <i>et al.</i>	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/731,528	
			Filing Date	December 9, 2003	
			First Named Inventor	Laszlo Prokai	
			Group Art Unit	1616	
			Examiner Name	Unknown	
Sheet	2	of	3	Attorney Docket Number	UF-340XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BREUER, H. and KOSTER, G., "Interaction Between Oestrogens and Neurotransmitters at the Hypophysial-Hypothalamic Level", <i>Journal of Steroid Biochemistry</i> , 1974, pp. 961-967, Vol. 5, Pergamon Press, Great Britain.	
	R2	GALDECKI, Z. <i>et al.</i> , "Structure of 2,4-Dibromo-10 $\beta$ , 17 $\beta$ -dihydroxy-1,4-estradien-3-one", <i>Acta Cryst.</i> , 1987, pp. 967-968, Vol. C43, International Union of Crystallography.	
	R3	HIEMKE, C. <i>et al.</i> , "Actions of Sex Hormones on the Brain", <i>Prog. Neuro-Psychopharmacol &amp; Biol. Psychiat.</i> , 1992, pp. 377-388, Vol. 16, Pergamon Press, Great Britain.	
	R4	KUPFER, R. <i>et al.</i> , "Comparisons of Hydroperoxide Isomerase and Monooxygenase Activities of Cytochrome P450 for Conversions of Allylic Hydroperoxides and Alcohols to Epoxyalcohols and Diols: Probing Substrate Reorientation in the Active Site", <i>Biochemistry</i> , 2001, pp. 11490-11501, Vol. 40, American Chemical Society.	
	R5	LIANG, Y. <i>et al.</i> , "Membrane Fluidity Effects of Estratrienes", <i>Brain Research Bulletin</i> , 2001, pp. 661-668, Vol. 54, No. 6, Elsevier Science Inc., USA.	
	R6	MCCULLOUGH, L. and HURN, P., "Estrogen and Ischemic Neuroprotection: an integrated view", <i>Trends in Endocrinology and Metabolism</i> , July 2003, pp. 228-235, Vol. 14, No. 5, Elsevier Science Inc.	
	R7	MILIC, D. <i>et al.</i> , "The Synthesis and Biological Evaluation of A-Ring Substituted Steroidal <i>p</i> -Quinones", <i>Tetrahedron</i> , 1997, pp. 14073-14084, Vol. 53, No. 41, Elsevier Science Ltd., Great Britain.	
	R8	MILIC, D. <i>et al.</i> , "Structure and Reactivity of Steroidal Quinones", <i>J. Serb. Chem. Soc.</i> , 1997, pp. 755-768, Vol. 62, No. 9.	
	R9	MILIC, D. <i>et al.</i> , "X-Ray Crystal Structure of 10 $\beta$ -Hydroxy-4 $\beta$ ,5 $\beta$ -epoxyestr-1-en-3,17-dione and Antitumor Activity of its Congeners", <i>Molecules</i> , 1999, pp. 338-352, Vol. 4, MDPI.	
	R10	NILSEN, J. and BRINTON, R., "Impact of Progestins on Estrogen-Induced Neuroprotection: Synergy by Progesterone and 19-Norprogesterone and Antagonism by Medroxyprogesterone Acetate", <i>Endocrinology</i> , 2002, pp. 205-212, Vol. 143, No. 1, The Endocrine Society, USA.	
	R11	NILSEN, J. and BRINTON R., "Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling", <i>PNAS</i> , September 2, 2003, pp. 10506-10511, Vol. 100, No. 18.	
	R12	NUMAZAWA, M. <i>et al.</i> , "Oxygenation of 2,4-Dibromoestrogens with Nitric Acid: A New Synthesis of 19-Nor Steroids", <i>Chem. Pharm Bull.</i> , 1989, pp. 2058-2062, Vol. 37, No. 8, Pharmaceutical Society of Japan.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/731,528		
		Filing Date	December 9, 2003		
		First Named Inventor	Laszlo Prokai		
		Group Art Unit	1616		
		Examiner Name	Unknown		
Sheet	3	of	3	Attorney Docket Number	UF-340XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R13	OHE, T. <i>et al.</i> , "Novel Metabolic Pathway of Estrone and 17 $\beta$ -Estradiol Catalyzed by Cytochrome P-450", <i>Drug Metabolism and Disposition</i> , 2000, pp. 110-112, Vol. 28, No. 2, The American Society for Pharmacology and Experimental Therapeutics, USA.	
	R14	PROKAI, L. <i>et al.</i> , "Targeting Drugs to the Brain by Redox Chemical Delivery Systems", <i>Med. Res. Rev.</i> , 2000, pp. 367-416, Vol. 20, No. 5, John Wiley & Sons, Inc.	
	R15	PROKAI, L. <i>et al.</i> , "Synthesis and Biological Evaluation of 17 $\beta$ -Alkoxyestra-1,3,5(10)-trienes as Potential Neuroprotectants Against Oxidative Stress", <i>J. Med. Chem.</i> , 2001, pp. 110-114, Vol. 44, American Chemical Society.	
	R16	PROKAI, L. <i>et al.</i> , "Quinol-based cyclic antioxidant mechanism in estrogen neuroprotein", <i>PNAS</i> , September 30, 2003, pp. 11741-11746, Vol. 100, No. 20.	
	R17	PROKAI, L. <i>et al.</i> , "Short Communication: Quinol-Based Metabolic Cycle for Estrogen in Rat Liver Microsomes", <i>Drug Metabolism and Disposition</i> , 2003, pp. 701-704, Vol. 31, No. 6, The American Society for Pharmacology and Experimental Therapeutics, USA.	
	R18	PROKAI-TATRAI, K. and PROKAI, L., "Modifying peptide properties by prodrug design for enhanced transport into the CNS", <i>Progress in Drug Research</i> , 2003, pp. 155-188, Vol. 61, Birkhäuser Verlag, Basel (Switzerland).	
	R19	SOLAJA, B. <i>et al.</i> , "A Novel <i>m</i> -CPBA Oxidation: <i>p</i> -Quinolns and Epoxyquinolns from Phenols", <i>Tetrahedron Letters</i> , 1996, pp. 3765-3768, Vol. 37, No. 21, Elsevier Science Ltd., Great Britain.	
	R20		
	R21		
	R22		
	R23		
	R24		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.